Definium Therapeutics, Inc. (MNMD) Form 10-Q — Aug 6, 2026
Definium Therapeutics (formerly Mind Medicine/MindMed) posted a Q2 2026 net loss of $159.0 million, or $1.44 per share, up from $42.7 million a year earlier, with about $86.2 million of the loss driven by a non-cash fair-value charge on its liability-classified 2022 USD Financing Warrants as the share price climbed to $47.04. Six-month net loss widened to $236.1 million from $66.1 million in the year-ago period. The balance sheet was transformed by a June 2026 offering of roughly 23.7 million shares at $34.00 that grossed $805.0 million ($757.9 million net), lifting cash and short-term investments to approximately $1.1 billion.
Key figures
- Total Assets
- 1112899000
- Cash Position
- 655267000
- Gross Proceeds
- 805000000
- Offering Price
- 34
- Shares Offered
- 23676471
- Shares Outstanding
- 134366950
- Q2 rnd expense
- 48665000
- Warrant expiry
- September 30, 2027
- Atm capacity 2024
- 150000000
- Accumulated deficit
- 818756000
- Six month ga expense
- 44148000
- Six month rnd expense
- 90149000
- Short term investments
- 428612000
- Total cash investments
- approximately $1.1 billion
- Warrant exercise price
- 4.25
- Credit facility maturity
- April 1, 2029
- October 2025 offering price
- 12.25
- Credit facility interest rate
- greater of 10.25% and Prime Rate + 2.75%
- Warrant liability jun 30 2026
- 113017000
- Shares outstanding dec 31 2025
- 98776265
- June 2026 offering net proceeds
- 757900000
- Share price assumption jun 30 2026
- 47.04
- October 2025 offering gross proceeds
- 258900000
- Credit facility principal outstanding
- 36500000
Price after filing
Close on the filing date to close N calendar days later (from $42.32). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.